Epilepsy Second Edition – Gregory D Cascino

Dam, M., Ekberg, R., Loyning, Y. et al. (1989). A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. 3 (1): 70–76. 52. Castillo, S., Schmidt, D.B., and White, S. (2000). Oxcarbazepine as add-on treatment for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 4: CD002028. 53. Vendrame, M., Khurana, D.S., Cruz, M. et al.

(2007). Aggravation of seizures and/or EEG features in children treated with oxcarbazepine monotherapy. Epilepsia 48 (11): 2116–2120. 54. Knapp, L.E. and Kugler, A.R. (1998). Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J. Child Neurol. 13 (Suppl 1): S15–S18; discussion 55. Mattson, R.H., Cramer, J.A., Collins, J.F. et al. (1985). Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic- clonic seizures.

N. Engl. J. Med. 313 (3): 145–151. 56. Zaccara, G., Gangemi, P.F., and Cincotta, M. (2008). Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 17 (5): 405–421. 57. Lozsadi, D., Hemming, K., and Marson, A.G. (2008). Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 1: CD005612. 58. Tassone, D.M., Boyce, E., Guyer, J., and Nuzum, D. (2007). Pregabalin: a novel gamma- aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.

Clin. Ther. 29 (1): 26–48. 59. Adkins, J.C. and Noble, S. (1998). Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 55 (3): 437–460. 60. Eckardt, K.M. and Steinhoff, B.J. (1998). Nonconvulsive status epilepticus in two patients receiving tiagabine treatment .

[see comments]. Epilepsia 39 (6): 671–674. 61. Sachdeo, R.C., Leroy, R.F., Krauss, G.L. et al. (1997). Tiagabine therapy for complex partial seizures. A dose-frequency study . The Tiagabine Study Group. Arch. Neurol. 54 (5): 595–601. 62. Uthman, B.M., Rowan, A.J., Ahmann, P.A. et al. (1998).

John Wiley & Sons (1e, 2011) All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions. The right of Gregory D. Cascino, Joseph I. Sirven and William O. Tatum to be identified as the author(s) of this the editorial material in this work has been asserted in accordance with law.

Registered Office(s) John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial Office 9600 Garsington Road, Oxford, OX4 2DQ, UK For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com. Wiley also publishes its books in a variety of electronic formats and by print‐on‐demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting scientific method, diagnosis, or treatment by physicians for any particular patient. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions.

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose.

No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services.

The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate.

This is a short excerpt from the opening of “” by Unknown, quoted for review and introduction purposes. All rights belong to the copyright holders.

Book Information

• Unique ID: b88d0d21277475bc
• File Extension: .pdf
• File Size: 23,196,580 bytes (22.122 MB)
• Title: –
• Author: Unknown
• ISBN: 9781119431824, 9781119431930, 9781119432005
• Pages: 514
• Language: English (en)

Reading & Word Statistics

• Estimated Reading Time: 925.02 minutes
• Total Words: 185,005
• Total Characters: 1,300,596
• Average Words per Page: 359.93
• Average Characters per Page: 2530.34

Most Frequent Words

epilepsy (3148), seizure (1227), seizures (1177), patients (986), eeg (599), temporal (468), focal (447), treatment (431), patient (406), clinical (400), neurology (386), surgery (368), brain (359), drug (357), sleep (353), associated (343), epilepsia (338), risk (333), also (329), syndrome (322), study (308), evaluation (293), lobe (288), mri (287), generalized (278), monitoring (269), children (269), onset (267), surgical (265), therapy (262), stimulation (262), doi (253), https (245), org (243), neurol (237), cortical (234), effects (233), epilepsies (230), disorders (227), one (227), potential (224), see (214), autoimmune (211), first (200), years (197), clinic (187), data (186), studies (185), often (183), use (181), diagnosis (180), antiepileptic (177), imaging (175), efficacy (175), mayo (172), epileptic (172), drugs (170), used (169), usa (165), include (164), however (163), figure (163), review (162), adults (161), etiology (160), events (159), side (158), history (157), genetic (157), age (154), devices (152), outcome (152), time (152), resection (146), between (145), diet (144), pediatric (143), two (143), including (142), medication (141), encephalitis (141), table (141), early (141), mesial (139), department (139), multiple (138), common (138), dose (134), classification (133), type (133), reported (133), women (131), right (130), testing (129), outcomes (128), sclerosis (127), interictal (127), activity (127), increased (127), factors (126).

PDF Download